Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Recombinant MPL- adjuvanted hepatitis B vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Recombinant MPL- adjuvanted hepatitis B vaccine | BIOLOGICAL | Intramuscular injection, 3 doses |
| Engerix™-B | BIOLOGICAL | Intramuscular injection, 3 doses |
Inclusion Criteria: * Age: older than 18 years of age. * Documented non-responders 2 to 5 months after having received 4 doses of a hepatitis B vaccine * Good physical condition as established by clinical examination and history taking at the time of entry. * Female participants who are at risk to ...
Recombinant MPL- adjuvanted hepatitis B vaccine is used for hepatitis B. It is an investigational vaccine being developed by GSK plc (GSK) and is currently in Phase 3 clinical development. The vaccine is designed to provide immunity against hepatitis B infection.
Recombinant MPL- adjuvanted hepatitis B vaccine is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in adult non-responders to existing hepatitis B vaccines.
Recombinant MPL- adjuvanted hepatitis B vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the vaccine is being studied for the prevention of hepatitis B.
Recombinant MPL- adjuvanted hepatitis B vaccine has one completed Phase 3 trial, NCT00697931, titled 'Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders'. The trial enrolled 116 participants in Belgium and compared the vaccine to an active control.
Recombinant MPL- adjuvanted hepatitis B vaccine is not the same as Engerix-B. In the clinical trial NCT00697931, the vaccine was compared against Engerix-B as an active control. The investigational vaccine includes an MPL adjuvant, while Engerix-B is a standard recombinant hepatitis B vaccine.
Recombinant MPL- adjuvanted hepatitis B vaccine is designed to stimulate an immune response against hepatitis B. It contains a recombinant hepatitis B surface antigen combined with an MPL adjuvant, which is intended to enhance the body's immune response. The vaccine is being studied in adults who did not respond to previous hepatitis B vaccination.